Table 2.
Comparison of Tissue Inhibitors of Metalloproteinase-1 Levels in Different Groups of Patients According to Gender, Heart Failure, Ejection Fraction, and Diabetes Mellitus
| Characteristics of the groups | TIMP-1 group A (nM) | TIMP-1 group B (nM) | p |
|---|---|---|---|
| TIMP-1/1 men vs. women | 107.70 | 117.0 | 0.02 |
| TIMP-1/2 men vs. women | 125.0 | 139.0 | 0.02 |
| TIMP-1/1 vs. TIMP-1/2 for men | 107.0 | 125.0 | <0.01 |
| TIMP-1/1 vs. TIMP-1/2 for women | 117.7 | 139.0 | <0.01 |
| TIMP-1/1 for men with AHF vs. without AHF | 123.0 | 101.0 | <0.01 |
| TIMP-1/2 for men with AHF vs. without AHF | 145.0 | 118.6 | <0.01 |
| TIMP-1/2 for men with EF<40% vs. EF>40% | 138.0 | 121.0 | <0.01 |
| TIMP-1/2 for women with AHF vs. without AHF | 145.4 | 135.0 | 0.05 |
| TIMP-1/1 for men with DM vs. without DM | 118.0 | 101.2 | <0.01 |
| TIMP-1/2 for men with DM vs. without DM | 137.0 | 121.0 | <0.01 |
| TIMP-1/2 for women with DM vs. without DM | 145.9 | 134.2 | <0.01 |
TIMP-1/1–level of TIMP-1 at admission; TIMP-1/2 level of TIMP-1 at 24 h after MI onset; TIMP, tissue inhibitors of metalloproteinase; EF, left ventricular ejection fraction; AHF, acute heart failure; DM, diabetes mellitus.